

### This week in therapeutics

| Indication   | Target/marker/pathway                   | Summary  | Licensing status                        | Publication and contact information  |
|--|---|--|---|--|
| <b>Various</b>   |   |  |   |  |
| Graft rejection; cancer  | SCF complex F-box protein MET30 (MET30) | <i>In vitro</i> studies identified a small molecule inhibitor of the MET30 E3 ubiquitin ligase that could be used as an adjuvant to increase the antiproliferative activity of Rapamune. A screen of 30,000 compounds identified several compounds that improved the efficacy of Rapamune in yeast. One of the inhibitors worked by blocking the function of the MET30 E3 ubiquitin ligase <i>in vitro</i> . Next steps include further <i>in vitro</i> and <i>in vivo</i> characterization of the compounds. Rapamune sirolimus, a mammalian target of rapamycin (mTOR; FRAP; RAFT1) inhibitor from Pfizer Inc., is marketed to prevent organ rejection in renal transplantation. | Patent and licensing status undisclosed | Aghajan, M. <i>et al. Nat. Biotechnol.</i> ; published online June 27, 2010; doi:10.1038/nbt.1645<br><b>Contact:</b> Jing Huang, University of California, Los Angeles, Calif.<br>e-mail: <a href="mailto:jinghuang@mednet.ucla.edu">jinghuang@mednet.ucla.edu</a><br><b>Contact:</b> Peter Kaiser, University of California, Irvine, Calif.<br>e-mail: <a href="mailto:pkaiser@uci.edu">pkaiser@uci.edu</a> |
| <p><i>SciBX</i> 3(27); doi:10.1038/scibx.2010.837<br/>Published online July 15, 2010</p> |   |  |   |  |